{
    "clinical_study": {
        "@rank": "72331", 
        "arm_group": {
            "arm_group_label": "MB and fluorescent imaging", 
            "arm_group_type": "Experimental", 
            "description": "Single arm study for the development of a protocol stipulating the optimum dose and time to peak near infra-red fluorescence from intraoperative injection of low dose Methylthioninium chloride"
        }, 
        "brief_summary": {
            "textblock": "Reliable identification of parathyroid glands is critical to the success of thyroid and\n      parathyroid surgery. In thyroid surgery, inadvertent injury to parathyroid glands may cause\n      temporary or permanent hypoparathyroidism (low calcium levels needing long term treatment).\n      In parathyroid surgery, early identification of normal and/or enlarged parathyroid glands\n      helps in deciding on the extent of surgery and increases the chances of postoperative normal\n      calcium levels.\n\n      Methylene Blue (Methylthioninium chloride, MB) is a dye that when given intravenously in\n      high doses, is taken up differently by thyroid and parathyroid tissue. It is currently used\n      during parathyroid surgery by some surgeons to help identify enlarged parathyroid glands by\n      visual examination alone. Such visual examination is unhelpful in the identification of\n      'normal' parathyroid tissue.  MB exhibits fluorescent properties in the near-infrared range\n      (light just beyond the visible spectrum). This can be picked up by an appropriate imaging\n      system. This has potential to identify and differentiate between 'normal' parathyroid,\n      'abnormal' parathyroid and thyroid tissue during surgery.\n\n      The investigators have established the feasibility of the intra-operative use of a near\n      infra-red fluorescent imaging device called Fluobeam\u00ae and demonstrated the ability of this\n      device to pick up near infra-red fluorescence from human tissue after administration of\n      intravenous MB. Animal experiments have shown that doses as low as 0.1mg/kg of MB given\n      intravenously enable fluorescent visualisation of thyroid and parathyroid glands.\n\n      This study will aim to optimise the dose and timing of administration of MB in human thyroid\n      and parathyroid surgery and to develop a protocol which would then subsequently be assessed\n      for effectiveness in a multi-centred randomized controlled setting."
        }, 
        "brief_title": "Intra-operative Infra-red Fluorescent Imaging in Thyroid and Parathyroid Surgery", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Total Thyroidectomy", 
            "Bilateral Neck Exploration for Primary Hyperparathyroidism"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hyperparathyroidism", 
                "Hyperparathyroidism, Primary"
            ]
        }, 
        "detailed_description": {
            "textblock": "Around 13,000 thyroid and parathyroid operations are performed per year in England for both\n      benign and malignant disease. Reliable identification of parathyroid glands is critical to\n      the success of thyroid and parathyroid surgery. In thyroid surgery, inadvertent injury to\n      parathyroid glands may cause temporary or permanent hypoparathyroidism (low calcium levels\n      needing long term treatment); the latter is associated with significant long term problems.\n      In parathyroid surgery, early identification of normal and/or enlarged parathyroid glands\n      helps in deciding on the extent of surgery and increases the chances of postoperative normal\n      calcium levels.\n\n      Methylene Blue (Methylthioninium chloride, MB) is a dye that when given intravenously in\n      high doses, is taken up differently by thyroid and parathyroid tissue. It is currently used\n      during parathyroid surgery by some surgeons to help identify enlarged parathyroid glands by\n      visual examination alone. At these doses, there is a risk of adverse effects from\n      administration of MB. Such visual examination is unhelpful in the identification of 'normal'\n      parathyroid tissue. MB is not currently used in surgery for thyroid pathologies.  MB\n      exhibits fluorescent properties in the near-infrared range (light just beyond the visible\n      spectrum). This can be picked up by an appropriate imaging system. This has potential to\n      identify and differentiate between 'normal' parathyroid, 'abnormal' parathyroid and thyroid\n      tissue during surgery.\n\n      The investigators have established the feasibility of the intra-operative use of a near\n      infra-red fluorescent imaging device called Fluobeam\u00ae and demonstrated the ability of this\n      device to pick up near infra-red fluorescence from human tissue after administration of\n      intravenous MB. Animal experiments have shown that doses as low as 0.1mg/kg of MB given\n      intravenously enable fluorescent visualisation of thyroid and parathyroid glands.\n\n      This study will aim to optimise the dose and timing of administration of MB in human thyroid\n      and parathyroid surgery and to develop a protocol which would then subsequently be assessed\n      for effectiveness in a multi-centred randomized controlled setting."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        -All patients undergoing either a total thyroidectomy or bilateral neck exploration for\n        PHPT in Sheffield Teaching Hospitals NHS Foundation Trust\n\n        Exclusion Criteria:\n\n          -  Patients undergoing re-do procedures\n\n          -  Patients unable to understand spoken and written English\n\n          -  Patients unable to give adequate informed consent\n\n          -  Patients with a history of intolerance or sensitivity to MB\n\n          -  Patients with known G6PD deficiency\n\n          -  Patients on serotonin reuptake inhibitors\n\n          -  Patients undergoing surgery for thyroglossal cyst and\n\n          -  Patients undergoing thoracic exploration; either alone or in combination with a neck\n             exploration"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02089542", 
            "org_study_id": "STH17176"
        }, 
        "intervention": {
            "arm_group_label": "MB and fluorescent imaging", 
            "description": "Single arm study for the development of a protocol stipulating the optimum dose and time to peak near infra-red fluorescence from intraoperative injection of low dose Methylthioninium chloride", 
            "intervention_name": "MB and fluorescent imaging", 
            "intervention_type": "Other", 
            "other_name": [
                "Methylthioninium chloride", 
                "Fluobeam 700 near infra-red imaging device"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Methylene Blue"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "thyroidectomy", 
            "parathyroid surgery", 
            "parathyroid identification", 
            "methylene blue", 
            "near infrared fluorescence", 
            "intraoperative imaging"
        ], 
        "lastchanged_date": "March 14, 2014", 
        "location": {
            "contact": {
                "email": "s.p.balasubramanian@sheffield.ac.uk", 
                "last_name": "Saba Balasubramanian, MS FRCS PhD", 
                "phone": "00441142261379"
            }, 
            "facility": {
                "address": {
                    "city": "Sheffield", 
                    "country": "United Kingdom", 
                    "state": "South Yorkshire", 
                    "zip": "S10 2JF"
                }, 
                "name": "Department of General Surgery"
            }, 
            "investigator": {
                "last_name": "Saba Balasubramanian, MS FRCS PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "Development of a Clinical Protocol to Use Intra-operative Near Infra-red Fluorescent Imaging in Thyroid and Parathyroid Surgery", 
        "other_outcome": [
            {
                "measure": "Postoperative calcium status", 
                "safety_issue": "No", 
                "time_frame": "up to 12 weeks of surgery"
            }, 
            {
                "description": "This will include any one of the following:\nDeath\nA life-threatening adverse event\nInpatient hospitalisation or prolongation of existing hospitalisation\nA disability / incapacity\nA congenital anomaly in the offspring of a participant The reporting period for Serious Adverse Events will be from the time of induction of anaesthetic until 30 days after the day of surgery. Important medical events that may not result in death, be life-threatening, or require hospitalisation may be considered a serious adverse event when, based upon appropriate medical judgment, they may jeopardize the patient or participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. All adverse events will be assessed for seriousness, expectedness and causality.", 
                "measure": "Serious adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "up to 30 days after surgery"
            }
        ], 
        "overall_contact": {
            "email": "erica.wallis@sth.nhs.uk", 
            "last_name": "Erica Wallis, MB,ChB", 
            "phone": "00441142265931"
        }, 
        "overall_official": {
            "affiliation": "University of Sheffield", 
            "last_name": "Saba Balasubramanian, MS FRCS PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Determine optimum dose of Methylene Blue that will enable fluorescence to be detected from the soft tissue structures in the neck", 
            "measure": "Optimum dose of Methylene Blue", 
            "safety_issue": "No", 
            "time_frame": "20 minutes"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02089542"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Time to peak fluorescence at varying doses of Methylene Blue will be assessed during the observation period, which will be a maximum of twenty minutes.", 
            "measure": "Time to peak fluorescence", 
            "safety_issue": "No", 
            "time_frame": "20 minutes"
        }, 
        "source": "Sheffield Teaching Hospitals NHS Foundation Trust", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sheffield Teaching Hospitals NHS Foundation Trust", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2014", 
        "study_design": "Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}